Vertex pays $950mm for diabetes-focused Semma

04 Sep 2019

Vertex Pharmaceuticals Inc. is paying $950mm in cash to acquire closely held diabetes-focused firm Semma Therapeutics Inc.

Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Intra-Biotech Deal
- Payment Includes Cash

Already a Biomedtracker subscriber? You have access to the full deal record through your subscription

Want to become a subscriber? Subscribers get more deal details, updates, deal financials and deal products.

Questions?

Please contact Sales at: (212) 520-2765 or email [email protected]

Related Companies

Vertex pays $950mm for diabetes-focused Semma

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

DCD.EmailPopout.Notice